Strata Critical Medical Inc Dossier
|
SectorHealth Care IndustryHealth Care Facilities Beta (adjusted)1.83 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $4.83Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $427.3M Enterprise Value $415.4M Shares Outstanding 87.3M diluted Moat Rating None Next Earnings Date9 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Strata Critical Medical, Inc. (formerly Blade Air Mobility) has successfully completed a radical corporate transformation by divesting its capital-intensive passenger business to Joby Aviation and re-emerging as a pure-play, high-margin logistics and clinical services provider dedicated to the organ transplant industry. The market has been slow to digest this transformation, leaving the stock undervalued relative to its high-growth MedTech peers. With strong organic growth in its core Logistics segment and high-margin expansion in Clinical services (such as Normothermic Regional Perfusion), Strata is uniquely positioned as a critical healthcare infrastructure provider. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$8.00 Mean target$9.25 High · most bullish analyst$11.50 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario Weather disruptions or seasonal headwinds severely impact air logistics volumes in key quarters. Integration of perfusion acquisitions faces operational friction, leading to higher SG&A expenses and margin compression. Regulatory changes from CMS negatively impact organ transport reimbursement rates. Base CaseCentral scenario The company successfully integrates its recent clinical acquisitions (Keystone, Ohio Valley, and Louisville Perfusion) and achieves its raised FY 2026 guidance of $260M-$275M in revenue and $29M-$33M in Adjusted EBITDA. Organic logistics growth remains robust above 20%, and clinical margins stabilize near 25%. Bull CaseUpside scenario Strata Critical Medical (SRTA) has successfully transitioned into a high-margin, pure-play medical logistics and clinical services provider dedicated to the organ transplant industry following the divestment of its capital-intensive passenger division to Joby Aviation. The company holds a highly defensible competitive moat as the only vertically integrated, end-to-end platform offering a bundled 'one call' solution (encompassing air/ground logistics, surgical organ recovery, organ placement, and normothermic regional perfusion). This unique positioning allows Strata to capture market share at multiple times the industry growth rate. Furthermore, strategic acquisitions (such as Keystone Perfusion/ProFusion, Louisville Perfusion Services, and the Heart and Lung Transplant National Recovery Program) expand its national footprint and drive significant revenue and margin expansion, positioning the company for a clear path to profitability and a projected high-teens organic Adjusted EBITDA CAGR in the medium term. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |